Despite the pause, the company clarified that the suspension does not impact commercial activity outside the US.

“On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and ...

The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA ...

Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.

Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

Qure.ai announced today that it appointed Jim Mercadante, a 25-year medtech veteran, as its new chief commercial officer (CCO ...

Mendaera announced today that it appointed surgical robotics veteran Eric Davidson as its first chief commercial officer (CCO ...

We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile ...

The global nailing systems market, valued at US$407.7 million in 2023, is forecasted to grow at a robust CAGR of 5.3%, ...